Stock Ratios
Making an investment decision in the stock market involves a certain amount of risk, so it's important to thoroughly review a company's stock before making any decisions. Stock float, number of short positions and outstanding shares are among the many factors an investor should take into account.
profit margin TTM
-651.62%
operating margin TTM
-933.58%
revenue TTM
10.23 Million
revenue per share TTM
0.17$
valuation ratios | |
|---|---|
| pe ratio | -25.34 |
| peg ratio | 2.70 |
| price to book ratio | 1.71 |
| price to sales ratio | 171.71 |
| enterprise value multiple | -23.00 |
| price fair value | 1.71 |
profitability ratios | |
|---|---|
| gross profit margin | 90.2% |
| operating profit margin | -933.58% |
| pretax profit margin | -651.62% |
| net profit margin | -651.62% |
| return on assets | -6.5% |
| return on equity | -9.22% |
| return on capital employed | -9.47% |
liquidity ratio | |
|---|---|
| current ratio | 59.21 |
| quick ratio | 59.21 |
| cash ratio | 24.66 |
efficiency ratio | |
|---|---|
| days of inventory outstanding | 0.00 |
| operating cycle | 185.50 |
| days of payables outstanding | 1,415.69 |
| cash conversion cycle | -1,230.19 |
| receivables turnover | 1.97 |
| payables turnover | 0.26 |
| inventory turnover | 0.00 |
debt and solvency ratios | |
|---|---|
| debt ratio | 0.02 |
| debt equity ratio | 0.02 |
| long term debt to capitalization | 0.00 |
| total debt to capitalization | 0.02 |
| interest coverage | 0.00 |
| cash flow to debt ratio | -1.90 |
cash flow ratios | |
|---|---|
| free cash flow per share | -0.78 |
| cash per share | 18.04 |
| operating cash flow per share | -0.77 |
| free cash flow operating cash flow ratio | 1.01 |
| cash flow coverage ratios | -1.90 |
| short term coverage ratios | 0.00 |
| capital expenditure coverage ratio | -122.04 |
Frequently Asked Questions
When was the last time Janux Therapeutics, Inc. (NASDAQ:JANX) reported earnings?
Janux Therapeutics, Inc. (JANX) published its most recent earnings results on 06-11-2024.
What is Janux Therapeutics, Inc.'s current ROE?
An investor's main concern is the profitability ratios of a company so that they are able to understand how it performs financially. Investors are interested in finding out how effectively a business is using their cash to produce earnings, which is why return on equity (ROE) ratio is important. Janux Therapeutics, Inc. (NASDAQ:JANX)'s trailing twelve months ROE is -9.22%.
What are ROA telling us?
The Return on Assets (ROA) ratio measures how profitable a company is relative to its total assets. Janux Therapeutics, Inc. (JANX) currently has a ROA of -6.5%. Companies that manage their assets effectively will have greater returns, while those that do so poorly would suffer lower returns.
Where did JANX's net profit margin stand at?
JANX reported a profit margin of -651.62% in the last quarter. A company's profit margin, also known as its revenue ratio or gross profit ratio, reflects the amount of revenue that an organization earns compared to its net income. In general, a higher ratio implies greater profit, and vice versa.
What is JANX's short-term liquidity position?
Apple's current ratio, which measures its ability to pay short-term obligations, was 59.21 in the most recent quarter. The quick ratio stood at 59.21, with a Debt/Eq ratio of 0.02.